Endometrial Cancer Recurrent
9
3
3
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
33.3%
3 terminated out of 9 trials
40.0%
-46.6% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (9)
A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer